Patent · US Active

Regulating chimeric antigen receptors

US11311609B2 · kind B2 · utility

1Cited by

10References

29Claims

0Family size

Assignee

DANA-FARBER CANCER INSTITUTE, INC. · US

Inventors

James E. Bradner · Weston, US
Justin Roberts · Cambridge, US
Behnam Nabet · Boston, US
Georg Winter · Brookline, US
Andrew J. Phillips · Arlington, US
Timothy Heffernan · Sugar Land, US
Dennis Buckley · Boston, US

Key dates

Filing date	Feb 8, 2018
Grant date	Apr 26, 2022
Priority date	—
Expiry date	Feb 8, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/95
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.